We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Gastroenterology

Journal Scan / Research · September 24, 2022

Semaglutide Monotherapy vs Semaglutide, Cilofexor, and/or Firsocostat Combination Therapy in Patients With NASH and Mild-to-Moderate Fibrosis

Journal of Hepatology


Additional Info

Journal of Hepatology
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial
J. Hepatol. 2022 Sep 01;77(3)607-618, N Alkhouri, R Herring, H Kabler, Z Kayali, T Hassanein, A Kohli, RS Huss, Y Zhu, AN Billin, LH Damgaard, K Buchholtz, MS Kjær, C Balendran, RP Myers, R Loomba, M Noureddin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading